SCHEMBL10043907

SCHEMBL10043907

Cc1cc2c(cn1)cc(-c1cc(C(=O)Nc3ccc(Cl)cn3)ccc1C)c(=O)n2C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.51
SMN1; SMN2 Q16637 6/20 0.51
TP53 P04637 4/20 0.51
TSHR P16473 3/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
MAPK1 P28482 2/20 0.48
KMT2A Q03164 4/20 0.48
POLB P06746 1/20 0.48
NPC1 O15118 8/20 0.46
ALDH1A1 P00352 3/20 0.46
PKM P14618 2/20 0.46
LMNA P02545 2/20 0.46
CYP2C19 P33261 3/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 2/20 0.45
ALOX15 P16050 2/20 0.45
CYP3A4 P08684 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043933 0.93 RAB9A (0.46) RAB9ASMN1; SMN2TP53TSHRNFKB1
SCHEMBL502061 0.91 CNR1 (0.48) RAB9ASMN1; SMN2TP53TSHRNFKB1
SCHEMBL502216 0.89 AHR (0.51) RXFP1MAPK14KDM4E
SCHEMBL10043926 0.87 MAPK14 (0.45) ALDH1A1RXFP1MAPK14
SCHEMBL10043913 0.86 RXFP1 (0.43) KMT2ARXFP1MAPK14MEN1
SCHEMBL10043912 0.86 NPC1 (0.51) RAB9ASMN1; SMN2TP53TSHRMAPK1
SCHEMBL10043942 0.85 PCTP (0.44) RAB9AKMT2ANPC1ALDH1A1MAPT
SCHEMBL10043897 0.84 ALDH1A1 (0.59) RAB9ASMN1; SMN2TP53TSHRMAPK1
SCHEMBL10043909 0.84 RAB9A (0.45) RAB9ASMN1; SMN2TP53TSHRNFKB1
SCHEMBL10043900 0.84 NPC1 (0.46) RAB9ASMN1; SMN2MAPK1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885SMN1; SMN2 2302/4885TP53 875/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885SMN1; SMN2 2302/4885TP53 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.